Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.54 |
| ▸ | PLK1 | P53350 | 12/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519038 | 0.89 | CHEK1 (0.57) | CHEK1PLK1KCNH2MEN1KMT2A | |
| SCHEMBL6513681 | 0.89 | CHEK1 (0.70) | CHEK1PLK1KCNH2ALDH1A1KDM4E | |
| SCHEMBL6513184 | 0.86 | CHEK1 (0.50) | CHEK1PLK1KCNH2MEN1KMT2A | |
| SCHEMBL6523201 | 0.86 | CHEK1 (0.52) | CHEK1PLK1KCNH2PIK3R1PIK3CA | |
| SCHEMBL6521294 | 0.84 | CHEK1 (0.50) | CHEK1PLK1KCNH2MEN1KMT2A | |
| SCHEMBL6515401 | 0.84 | CHEK1 (0.69) | CHEK1PLK1KCNH2ALDH1A1KDM4E | |
| SCHEMBL6519912 | 0.83 | CHEK1 (0.68) | CHEK1PLK1KCNH2ALDH1A1KDM4E | |
| SCHEMBL6518189 | 0.83 | CHEK1 (0.77) | CHEK1PLK1KCNH2ALDH1A1LMNA | |
| SCHEMBL6514012 | 0.80 | CHEK1 (0.45) | CHEK1PLK1KCNH2ALDH1A1KDM4E | |
| SCHEMBL6513056 | 0.79 | CHEK1 (0.68) | CHEK1PLK1KCNH2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885PLK1 151/4885KCNH2 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.